Editas Medicine, Inc (EDIT)

Etorro trading 970x250
Editas Medicine, Inc (EDIT) Logo

About Editas Medicine, Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Address: 11 Hurley Street, Cambridge, MA, United States, 02141

Editas Medicine, Inc News and around…

Latest news about Editas Medicine, Inc (EDIT) common stock and company :

Here is What Hedge Funds Think About Editas Medicine, Inc. (EDIT)
14 Jan, 2022 Yahoo! Finance

The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30th. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

First Week of EDIT March 4th Options Trading
14 Jan, 2022 FinancialContent

Investors in Editas Medicine Inc (EDIT) saw new options become available this week, for the March 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new March 4th contracts and identified one put and one call contract of particular interest.

What Kind Of Investors Own Most Of Editas Medicine, Inc. (NASDAQ:EDIT)?
14 Jan, 2022 Yahoo! Finance

If you want to know who really controls Editas Medicine, Inc. ( NASDAQ:EDIT ), then you'll have to look at the makeup...

Why Editas Medicine Stock Is Tumbling This Week
13 Jan, 2022 FinancialContent

The overall sell-off of biotech stocks appears to be the main culprit.

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To These CRISPR Stocks
13 Jan, 2022 Yahoo! Finance

CRISPR stocks will face make-or-break moments in 2022 as Big Pharma joins their quest to cure serious diseases with gene editing technology.

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
13 Jan, 2022 FinancialContent

CRISPR stocks will face make-or-break moments in 2022 as Big Pharma joins their quest to cure serious diseases with gene editing technology.

The Gene-Editing Industry Weighs In on Outlook at J.P. Morgan Conference
11 Jan, 2022 Yahoo! Finance

Companies like Intellia Therapeutics and Editas Medicine are saying that this year will bring exciting developments.

Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference
10 Jan, 2022 Yahoo! Finance

James C. Mullen James C. Mullen, Chairman, President, and Chief Executive Officer of Editas Medicine Anticipated 2022 milestones include initial clinical data for EDIT-301 in sickle cell disease by year-end, dosing of first TDT patient with EDIT-301, initiation of pediatric high-dose cohort for EDIT-101 in LCA10, and a clinical data update on EDIT-101 in the second half of 2022 Company announces new development candidates EDIT-103 for RHO-adRP and EDIT-202 multiplexed iNK cell therapy for solid

First Week of February 25th Options Trading For Editas Medicine (EDIT)
07 Jan, 2022 FinancialContent

Investors in Editas Medicine Inc (EDIT) saw new options begin trading this week, for the February 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new February 25th contracts and identified one put and one call contract of particular interest.

Notable Thursday Option Activity: EDIT, AXSM, PTON
06 Jan, 2022 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Editas Medicine Inc (EDIT), where a total of 8,110 contracts have traded so far, representing approximately 811,000 underlying shares. That amounts to about 53.3% of EDIT's average daily trading volume over the past month of 1.5 million shares..

Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 Jan, 2022 Yahoo! Finance

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the 40th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 12, 2022, at 10:30 a.m. ET A live webcast of the presentation will be available on the Investors section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website fo

Stocks Hitting New 52-Week Lows Today
03 Jan, 2022 FinancialContent

On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows ...

First Week of EDIT February 11th Options Trading
03 Jan, 2022 FinancialContent

Investors in Editas Medicine Inc (EDIT) saw new options become available this week, for the February 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new February 11th contracts and identified one put and one call contract of particular interest.

Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
22 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips 2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year. The post Top 5 Moonshots for 2022 Countdown: My No. 5 Pick appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

First Week of August 2022 Options Trading For Editas Medicine (EDIT)
20 Dec, 2021 FinancialContent

Investors in Editas Medicine Inc (EDIT) saw new options begin trading this week, for the August 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Dr. Jessica Hopfield Appointed to Berkeley Lights Board of Directors
20 Dec, 2021 Yahoo! Finance

Addition of Experienced Independent Director with Accomplished Business Record Underscores Berkeley Lights Board of Directors’ Commitment to Delivering Value for ShareholdersEMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights’ Board of Directors as an independent director, effective December 15, 2021. "Dr. Hopfield is a respected and accomplis

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia
20 Dec, 2021 Yahoo! Finance

EDIT-301 is in development as a transformative, one-time treatment for people living with transfusion-dependent beta thalassemia Editas Medicine will initiate a Phase 1/2 clinical trial in 2022 CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for EDIT-301 for the treatment of transfusion-dependent beta thalassemia (TDT), enabling the Comp

uniQure (QURE) Falls on Data From Huntington's Disease Study
17 Dec, 2021 Yahoo! Finance

uniQure (QURE) reports initial data on the first four patients enrolled in the lower-dose cohort of its ongoing phase I/II clinical trial of AMT-130 for treating Huntington's disease.

10 Best Genomics Stocks to Buy Now
17 Dec, 2021 Yahoo! Finance

In this article, we will discuss the 10 best genomics stocks to buy now. You can skip our detailed analysis of these stocks and go directly to the 5 Best Genomics Stocks to Buy Now. Genomics is the branch of biology that deals with the study of human genes. The genome is the complete set […]

Bristol Myers' (BMY) Orencia Gets FDA Nod for New Indication
16 Dec, 2021 Yahoo! Finance

The FDA approves Bristol Myers' (BMY) Orencia in combination with a calcineurin inhibitor and methotrexate to prevent acute graft versus host disease. This is the fourth FDA-approved indication for the drug.

Apellis (APLS), Sobi Get EU Nod for Rare Blood Disorder Drug
16 Dec, 2021 Yahoo! Finance

The European Commission approves Apellis (APLS) and Sobi's Aspaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients. Shares rise.

Alnylam (ALNY) Files for Oxlumo Label Expansion in US & EU
15 Dec, 2021 Yahoo! Finance

Alnylam (ALNY) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.

Trevena (TRVN) to Begin Clinical Study on Pain Candidate
14 Dec, 2021 Yahoo! Finance

Trevena (TRVN) advances TRV045 into clinical development as a potential treatment for diabetic neuropathic pain. Enrollment in the study is expected to begin in the first quarter of 2022.

First Week of EDIT January 2022 Options Trading
13 Dec, 2021 FinancialContent

Investors in Editas Medicine Inc (EDIT) saw new options begin trading this week, for the January 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain for the new January 2022 contracts and identified one put and one call contract of particular interest.

NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today
13 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nuverra Environmental (NES) stock is surging higher on Monday following news of a massive deal with Select Energy Services (WTTR). The post NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today
13 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937. The post BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today
13 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips After falling 60% year to date, EDIT stock is finally reversing course and trending higher in morning trading. The post EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

22 Stocks Moving in Monday's Pre-Market Session
13 Dec, 2021 FinancialContent

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on ...

Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting
12 Dec, 2021 Yahoo! Finance

Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors iNKs with double knock-in of CD16 and mbIL-15 in combination with monoclonal antibodysignificantly reduce tumor burden iNKs with double knock-out of CISH and TGFβR2 substantially reduce tumor burden CAMBRIDGE, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome

Cytokinetics' (CYTK) Aficamten Gets Breakthrough Therapy Tag
10 Dec, 2021 Yahoo! Finance

The FDA bestows a Breakthrough Therapy status on Cytokinetics' (CYTK) aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Editas Medicine, Inc (EDIT) is a NASDAQ Common Stock listed in , ,

970x250